Table 4.

Summary of the demographic and clinical data by T2-lesion load quartiles

	Q1	Q2	Q3	Q4
T2-Lesion load (mm3)	N = 126	N = 126	N = 126	N = 125
	Mean = 335.07	Mean = 1889.45	Mean = 5336.18	Mean = 22016.27
	SD = 254.38	SD = 631.06	SD = 1527.66	SD = 15222.37
	Median = 297.62	Median = 1882.95	Median = 5121.50	Median = 16386.55
	Range: 0–887.92	Range: 915.60–3082.32	Range: 3119.24–8738.09	Range: 8864.65–87641.24
Age (Y)	N = 125	N = 125	N = 126	N = 125
P = 0.030	Mean = 39.9	Mean = 41.9	Mean = 42.8	Mean = 43.7
	SD = 9.1	SD = 9.6	SD = 9.7	SD = 10.8
	Median = 40.0	Median = 42.0	Median = 41.5	Median = 43.0
	Range: 17–65	Range: 18–64	Range: 23–63	Range: 19–65
Gender	F: 87 (25.5%)	F: 87 (25.5%)	F: 88 (25.8%)	F: 79 (23.2%)
P = 0.652	M: 39 (24.1%)	M: 39 (24.0%)	M: 38 (23.5%)	M: 46 (28.4%)
Age at disease onset (Y)	N = 125	N = 125	N = 126	N = 125
P < 0.0001	Mean = 34.5	Mean = 35.2	Mean = 33.6	Mean = 30.3
	SD = 8.6	SD = 8.6	SD = 9.7	SD = 9.4
	Median = 35.0	Median = 35.0	Median = 32.0	Median = 29.7
	Range: 13–55	Range: 17–58	Range: 17–60	Range: 11–58
Disease duration (Y)	N = 125	N = 125	N = 126	N = 125
P < 0.0001	Mean = 6.5	Mean = 7.7	Mean = 10.2	Mean = 14.4
	SD = 6.5	SD = 7.1	SD = 8.6	SD = 10.7
	Median = 4.0	Median = 5.0	Median = 7.0	Median = 12.0
	Range: 1–35	Range: 1–38	Range: 1–37	Range: 1–46
MS treatment exposure	NO: 59 (47.2%)	NO: 36 (28.8%)	NO: 34 (27.0%)	NO: 27 (21.6%)
P < 0.0001	YES: 66 (52.8%)	YES: 89 (71.2%)	YES: 92 (73.0%)	YES: 98 (78.4%)
HLA-DRB1*1501	1501+: 45 (19.7%)	1501+: 64 (28.0%)	1501+: 62 (27.2%)	1501+: 57 (25.0%)
P = 0.066	1501−: 80 (29.4%)	1501−: 61 (22.4%)	1501−: 62 (22.8%)	1501−: 69 (25.4%)
EDSS score	N = 125	N = 125	N = 126	N = 125
P < 0.0001	Mean = 1.58	Mean = 1.77	Mean = 1.97	Mean = 2.72
	SD = 1.50	SD = 1.46	SD = 1.43	SD = 1.93
	Median = 1.5	Median = 1.5	Median = 1.5	Median = 2.0
	Range: 0–7	Range: 0–6	Range: 0–6	Range: 0–7

Y = years; F = female; M = male; EDSS = expanded disability status scale.